Attenuation Effect of Cannabinoid Type 1 Receptor Activation on Methamphetamine-Induced Neurodegeneration and Locomotion Impairments among Male Rats

Document Type : Original Article(s)


1 PhD Candidate, Department of Physiology AND Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

2 Professor, Department of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

3 Pharmacist, Intracellular Recording Lab, Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran

4 Professor, Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran

5 Professor, Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

6 Assistant Professor, Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran

7 Associate Professor, Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran


Background: A number of neuroimaging studies on human addicts have revealed that abuse of Methamphetamine (METH) can induce neurodegenerative changes in various brain regions like the cerebral cortex and cerebellum. Although the underlying mechanisms of METH-induced neurotoxicity have been studied, the cellular and molecular mechanisms of METH-induced neurotoxicity remain to be clarified. Previous studies implicated that cannabinoid type 1 receptors (CB1Rs) exert neuroprotective effects on several models of cerebral toxicity, but their role in METH-induced neurotoxicity has been rarely investigated. Moreover, the cerebellum was considered as a potential target to evaluate the effects of cannabinoids on locomotion activity as the CB1Rs are most widely distributed in the molecular layer of cerebellum. Therefore, the present study was carried out to evaluate whether neurodegeneration induced in the cerebellum tissue implicated in locomotion deficit induced by METH.Methods: In the current study, open field test was used to examine locomotor activity. Using hematoxylin and eosin (H&E) staining, morphology of the cerebellar vermis was investigated after repeated exposure to METH. Then, the effects of CB1Rs antagonist [SR17141A, 10 mg/kg, intraperitoneally (IP)] and CB1Rs agonist [WIN55, 212-2 (WIN), 3 mg/kg] against METH-induced neurodegeneration and locomotor deficit were assessed.Findings: The results of the present study demonstrated that repeated exposure to METH increased cerebellar degeneration level as compared to the saline and dimethyl sulfoxide (DMSO) groups. In addition, METH-treated rats showed hyperactivity as compared to the saline and DMSO groups. Pretreatment with WIN significantly attenuated neurodegeneration and hyperactivity induced by METH.Conclusion: The findings of this study provided evidence that CB1Rs may serve as a therapeutic strategy for attenuation of METH-induced locomotor deficits.


  1. Serrano A, Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 2011; 132(3): 215-41.
  2. Jan RK, Kydd RR, Russell BR. Functional and structural brain changes associated with methamphetamine abuse. Brain Sci 2012; 2(4): 434-82.
  3. Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology 2010; 58(1): 38-43.
  4. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev 2009; 60(2): 379-407.
  5. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment. Drug Alcohol Depend 2015; 146: 30-8.
  6. Tulloch IK, Afanador L, Baker L, Ordonez D, Payne H, Mexhitaj I, et al. Methamphetamine induces low levels of neurogenesis in striatal neuron subpopulations and differential motor performance. Neurotox Res 2014; 26(2): 115-29.
  7. Wu CW, Ping YH, Yen JC, Chang CY, Wang SF, Yeh CL, et al. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicol Appl Pharmacol 2007; 220(3): 243-51.
  8. Schweighofer N, Doya K, Kuroda S. Cerebellar aminergic neuromodulation: Towards a functional understanding. Brain Res Brain Res Rev 2004; 44(2-3): 103-16.
  9. Ma YL, Weston SE, Whalley BJ, Stephens GJ. The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol 2008; 154(1): 204-15.
  10. Bortolato M, Frau R, Bini V, Luesu W, Loriga R, Collu M, et al. Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB(1) cannabinoid receptors. J Psychiatr Res 2010; 44(14): 944-55.
  11. Rustay NR, Wahlsten D, Crabbe JC. Influence of task parameters on rotarod performance and sensitivity to ethanol in mice. Behav Brain Res 2003; 141(2): 237-49.
  12. Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M. Cannabinoids and tremor induced by motor-related disorders: Friend or foe? Neurotherapeutics 2015; 12(4): 778-87.
  13. Vazquez-Sanroman D, Leto K, Cerezo-Garcia M, Carbo-Gas M, Sanchis-Segura C, Carulli D, et al. The cerebellum on cocaine: Plasticity and metaplasticity. Addict Biol 2015; 20(5): 941-55.
  14. Ramirez-Franco J, Bartolome-Martin D, Alonso B, Torres M, Sanchez-Prieto J. Cannabinoid type 1 receptors transiently silence glutamatergic nerve terminals of cultured cerebellar granule cells. PLoS One 2014; 9(2): e88594.
  15. Abbassian H, Esmaeili P, Tahamtan M, Aghaei I, Vaziri Z, Sheibani V, et al. Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor. Physiol Behav 2016; 164(Pt A): 314-20.
  16. Abbassian H, Whalley BJ, Sheibani V, Shabani M. Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br J Pharmacol 2016; 173(22): 3196-207.
  17. Shabani M, Nazeri M, Parsania S, Razavinasab M, Zangiabadi N, Esmaeilpour K, et al. Walnut consumption protects rats against cisplatin-induced neurotoxicity. Neurotoxicology 2012; 33(5): 1314-21.
  18. Razavinasab M, Shamsizadeh A, Shabani M, Nazeri M, Allahtavakoli M, Asadi-Shekaari M, et al. Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson's disease. Fundam Clin Pharmacol 2013; 27(6): 632-40.
  19. Abbasloo A, Wiens V, Hermann M, Schultz T. Visualizing tensor normal distributions at multiple levels of detail. IEEE Trans Vis Comput Graph 2016; 22(1): 975-84.
  20. Lee SH, Kim SJ, Kim GE, Lee WJ, Hong WK, Baik GH, et al. Calcium polystyrene sulfonate induced colonic necrosis in patient with chronic kidney disease. Korean J Gastroenterol 2010; 55(4): 261-5.
  21. Mendieta L, Granado N, Aguilera J, Tizabi Y, Moratalla R. Fragment C domain of tetanus toxin mitigates methamphetamine neurotoxicity and its motor consequences in mice. Int J Neuropsychopharmacol 2016; 19(8).
  22. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, et al. Why is parkinsonism not a feature of human methamphetamine users? Brain 2004; 127(Pt 2): 363-70.
  23. Caligiuri MP, Buitenhuys C. Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype? Neuropsychopharmacology 2005; 30(12): 2125-34.
  24. DeSanty KP, Dar MS. Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice. Pharmacol Biochem Behav 2001; 69(1-2): 251-9.
  25. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158(3): 377-82.
  26. Salo R, Fassbender C, Iosif AM, Ursu S, Leamon MH, Carter C. Predictors of methamphetamine psychosis: History of ADHD-relevant childhood behaviors and drug exposure. Psychiatry Res 2013; 210(2): 529-35.
  27. Abulseoud OA, Miller JD, Wu J, Choi DS, Holschneider DP. Ceftriaxone upregulates the glutamate transporter in medial prefrontal cortex and blocks reinstatement of methamphetamine seeking in a condition place preference paradigm. Brain Res 2012; 1456: 14-21.
  28. Bowyer JF, Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006; 60(7): 521-32.
  29. Thomas DM, Francescutti-Verbeem DM, Liu X, Kuhn DM. Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment-an oligonucleotide microarray approach. J Neurochem 2004; 88(2): 380-93.
  30. Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 2005; 8(3-4): 199-206.
  31. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008; 151(2): 533-43.
  32. Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, et al. Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine. Behav Brain Res 2014; 270: 261-9.
  33. Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP. Delta(9)-tetrahydrocannabinol (Delta(9)-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathol Appl Neurobiol 2012; 38(6): 535-47.
  34. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013; 64: 21-47.
  35. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. Delta9 tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 2007; 1128(1): 61-9.